Zacks: Analysts Anticipate Heat Biologics, Inc. (NASDAQ:HTBX) Will Post Quarterly Sales of $570,000.00

Analysts expect Heat Biologics, Inc. (NASDAQ:HTBX) to report $570,000.00 in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Heat Biologics’ earnings, with the highest sales estimate coming in at $800,000.00 and the lowest estimate coming in at $400,000.00. Heat Biologics posted sales of $850,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 32.9%. The company is expected to report its next quarterly earnings results on Monday, November 8th.

On average, analysts expect that Heat Biologics will report full year sales of $2.35 million for the current year, with estimates ranging from $1.80 million to $2.94 million. For the next financial year, analysts anticipate that the company will report sales of $0.00. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Heat Biologics.

Heat Biologics (NASDAQ:HTBX) last announced its earnings results on Tuesday, August 10th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.05. Heat Biologics had a negative net margin of 1,198.17% and a negative return on equity of 23.43%.

Several equities research analysts have issued reports on HTBX shares. B. Riley lifted their target price on shares of Heat Biologics from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, August 18th. Alliance Global Partners decreased their price target on shares of Heat Biologics from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, August 25th.

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC increased its stake in shares of Heat Biologics by 98.0% in the second quarter. Virtu Financial LLC now owns 37,152 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 18,387 shares during the period. Morgan Stanley increased its stake in shares of Heat Biologics by 690.8% in the second quarter. Morgan Stanley now owns 66,426 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 58,026 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Heat Biologics in the second quarter worth $127,000. State Street Corp increased its stake in shares of Heat Biologics by 466.5% in the second quarter. State Street Corp now owns 98,896 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 81,440 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Heat Biologics by 10.4% in the second quarter. Northern Trust Corp now owns 46,831 shares of the biopharmaceutical company’s stock worth $315,000 after buying an additional 4,422 shares during the period. 10.38% of the stock is currently owned by hedge funds and other institutional investors.

Heat Biologics stock traded down $0.23 during mid-day trading on Friday, hitting $6.14. 12,140 shares of the company traded hands, compared to its average volume of 1,292,898. Heat Biologics has a one year low of $5.22 and a one year high of $17.00. The stock has a fifty day moving average price of $6.47 and a 200-day moving average price of $6.87.

Heat Biologics Company Profile

Heat Biologics, Inc, a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

Featured Article: What is a stock portfolio tracker?

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heat Biologics (NASDAQ:HTBX)

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.